LTRN Lantern Pharma Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1763950 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY3.1%
TTM EPS YoY8.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-400.9%
ROA-143.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets137.4%
Debt / equity—
Current ratio1.96x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-35.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $11.51M | $16.13M | $11.89M | $8.60M | $7.57M |
| SG&A expense | $6.46M | $6.09M | $5.98M | $5.83M | $5.02M |
| Operating income | -$17.98M | -$22.22M | -$17.88M | -$14.43M | -$12.59M |
| Pretax income | $16.98M | — | — | — | — |
| Net income | -$17.12M | -$20.78M | -$15.96M | -$14.26M | -$12.36M |
| EBITDA | -$17.96M | -$22.20M | -$17.86M | -$14.42M | -$12.58M |
| EPS (basic) | -1.57 | -1.93 | -1.47 | -1.31 | -1.13 |
| EPS (diluted) | -1.57 | -1.93 | -1.47 | -1.31 | -1.13 |
| Weighted avg. shares (diluted) | 10.90M | 10.76M | 10.84M | 10.85M | 10.90M |
| Balance sheet | |||||
| Cash & equivalents | $4.42M | $7.51M | $21.94M | $37.20M | $51.52M |
| Short-term investments | $5.70M | $16.50M | $19.36M | $17.99M | $19.20M |
| Current assets | $10.80M | $25.25M | $43.34M | $58.72M | $72.72M |
| PP&E, net | $31,875 | $47,440 | $52,127 | $48,008 | $30,245 |
| Total assets | $11.04M | $25.57M | $43.65M | $58.84M | $73.95M |
| Current liabilities | $4.50M | $4.33M | $2.68M | $2.80M | $2.33M |
| Total liabilities | $4.50M | $4.38M | $2.74M | $2.80M | $2.38M |
| Shareholders' equity | $6.53M | $21.19M | $40.91M | $56.04M | $71.57M |
| Shares outstanding | 11.25M | 10.78M | 10.72M | 10.86M | 11.09M |
| Cash flow statement | |||||
| Operating cash flow | -$15.68M | -$17.81M | -$14.35M | -$12.77M | -$10.59M |
| Capital expenditure | $1,715 | $12,595 | $18,734 | $27,844 | $15,499 |
| Free cash flow | -$15.68M | -$17.83M | -$14.37M | -$12.80M | -$10.61M |
| Investing cash flow | $11.06M | $3.37M | -$930,210 | $179,268 | -$19.53M |
| Financing cash flow | $1.50M | $66,710 | -$499,997 | -$2.18M | $63.42M |
| Depreciation & amortization | $17,280 | $17,282 | $14,615 | $10,081 | $6,761 |
| Stock-based compensation | $651,000 | $652,000 | $1.02M | $1.19M | $961,545 |
| Share buybacks | — | — | $499,997 | $2.48M | $939,666 |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.